ライフサイエンスコーパス: castration-resistant prostate cancer

1 en receptor (AR) may play a critical role in castration resistant prostate cancer.

2 RT) for the treatment of liver metastases of castration-resistant prostate cancer.

3 o centres in men with progressive metastatic castration-resistant prostate cancer.

4 for clinical translation to treat metastatic castration-resistant prostate cancer.

5 ity of DSTP3086S in patients with metastatic castration-resistant prostate cancer.

6 ectomy, and cohort B patients had metastatic castration-resistant prostate cancer.

7 overall survival in patients with metastatic castration-resistant prostate cancer.

8 proach to treat metastatic hormone-naive and castration-resistant prostate cancer.

9 nd consequent cell proliferation, leading to castration-resistant prostate cancer.

10 le and may contribute to the genetic risk of castration-resistant prostate cancer.

11 astasis and death in men with nonmetastatic, castration-resistant prostate cancer.

12 ay ultimately lead to a new therapy for AR+, castration-resistant prostate cancer.

13 d with improved overall survival in men with castration-resistant prostate cancer.

14 om initial diagnosis to advanced, metastatic castration-resistant prostate cancer.

15 lpha-therapy for the treatment of metastatic castration-resistant prostate cancer.

16 rivation therapy and in approximately 30% of castration-resistant prostate cancer.

17 CBP/p300 bromodomain as a strategy to treat castration-resistant prostate cancer.

18 in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer.

19 d not improve OS in patients with metastatic castration-resistant prostate cancer.

20 the RLT and care of patients with metastatic castration-resistant prostate cancer.

21 P/p300 is required to maintain the growth of castration-resistant prostate cancer.

22 ith mitoxantrone in patients with metastatic castration-resistant prostate cancer.

23 overall survival in patients with metastatic castration-resistant prostate cancer.

24 erapeutic option in patients with metastatic castration-resistant prostate cancer.

25 rials that enrolled patients with metastatic castration-resistant prostate cancer.

26 6 signaling as a central mechanism mediating castration-resistant prostate cancer.

27 ion that provided new insights in metastatic castration-resistant prostate cancer.

28 3 is a potential target for the treatment of castration-resistant prostate cancer.

29 and is approved for patients with metastatic castration-resistant prostate cancer.

30 sing antitumor effect in advanced metastatic castration-resistant prostate cancer.

31 1, 2009, and July 31, 2013, with metastatic castration-resistant prostate cancer.

32 to licensing for the treatment of metastatic castration-resistant prostate cancer.

33 nt further studies of 6 for the treatment of castration-resistant prostate cancer.

34 ion that provided new insights in metastatic castration-resistant prostate cancer.

35 symptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.

36 tandard of care for patients with metastatic castration-resistant prostate cancer.

37 e therapy response and prognosis in men with castration-resistant prostate cancer.

38 ith bicalutamide in patients with metastatic castration-resistant prostate cancer.

39 only agent with proven survival benefit for castration-resistant prostate cancer.

40 undergoing further development in metastatic castration-resistant prostate cancer.

41 chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

42 nt in chemotherapy-naive men with metastatic castration-resistant prostate cancer.

43 tivity is the main driver for development of castration-resistant prostate cancer.

44 e treatment of androgen-sensitive as well as castration-resistant prostate cancer.

45 onal activity and promote the development of castration-resistant prostate cancer.

46 validated therapeutic target for metastatic castration-resistant prostate cancer.

47 o improvement in the treatment of metastatic castration-resistant prostate cancer.

48 patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

49 chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

50 tamide, a drug approved for the treatment of castration-resistant prostate cancer.

51 for chemotherapy-naive men with metastatic, castration-resistant prostate cancer.

52 navir or its analogs should be developed for castration-resistant prostate cancer.

53 tment failure and poor outcome in metastatic castration-resistant prostate cancer.

54 approved for the treatment of nonmetastatic, castration-resistant prostate cancer.

55 regulatory role of methylation in metastatic castration-resistant prostate cancer.

56 rated with Pten loss to drive AR-independent castration-resistant prostate cancer.

57 t a new therapeutic target in the metastatic castration-resistant prostate cancer.

58 se II trial involving 30 men with metastatic castration-resistant prostate cancer.

59 eatment response in patients with metastatic castration-resistant prostate cancer.

60 tions and response to olaparib in metastatic castration-resistant prostate cancer.

61 n emerging treatment modality for metastatic castration-resistant prostate cancer.

62 ll as in androgen-dependent tumours, such as castration-resistant prostate cancer.

63 ific membrane antigen (PSMA) in metastasized castration-resistant prostate cancer.

64 ee survival in patients with non-metastatic, castration-resistant prostate cancer.

65 presenting with high-risk, non- metastatic, castration-resistant prostate cancer.

66 th cabazitaxel alone for men with metastatic castration-resistant prostate cancer.

67 it had no effect on OS or AWE in metastatic castration-resistant prostate cancer.

68 improve the outcomes of men with metastatic castration-resistant prostate cancer.

69 llows functional substitution for AR in some castration-resistant prostate cancers.

70 etastasis is the hallmark of progressive and castration-resistant prostate cancers.

71 Treatment of advanced metastatic castration-resistant prostate cancer after failure of ap

72 se 3 trial involving men with nonmetastatic, castration-resistant prostate cancer and a prostate-spec

73 aged 18 years or older with non-metastatic, castration-resistant prostate cancer and a prostate-spec

74 vation therapy among men with nonmetastatic, castration-resistant prostate cancer and a rapidly risin

75 labeled PSMA-617 in patients with metastatic castration-resistant prostate cancer and a single functi

76 esponses in asymptomatic men with metastatic castration-resistant prostate cancer and also resensitis

77 symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases

78 keletal event-free survival in patients with castration-resistant prostate cancer and bone metastases

79 py-naive, asymptomatic or mildly symptomatic castration-resistant prostate cancer and bone metastases

80 le for participation if they had: metastatic castration-resistant prostate cancer and had received no

81 ional program in both androgen-sensitive and castration-resistant prostate cancer and inhibited tumou

82 ety and survival of patients with metastatic castration-resistant prostate cancer and liver metastase

83 cruited patients with progressive metastatic castration-resistant prostate cancer and no previous che

84 ee survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increas

85 sly reported ALSYMPCA trial in patients with castration-resistant prostate cancer and symptomatic bon

86 en receptor-regulated miRNA overexpressed in castration-resistant prostate cancer and that miR-32 can

87 role for BAT in the management of metastatic castration-resistant prostate cancer and the optimal str

88 It occurred in both androgen-dependent and castration-resistant prostate cancer and was associated

89 in human NEPC tumors compared to primary and castration-resistant prostate cancers, and its expressio

90 ditional cohorts (post-abiraterone and newly castration-resistant prostate cancer) are ongoing.

91 us prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim anal

92 (1245A>C) has been mechanistically linked to castration-resistant prostate cancer because it encodes

93 A subset of castration resistant prostate cancers become androgen re

94 a-118b, a patient-derived xenograft (PDX) of castration-resistant prostate cancer bone metastasis tha

95 tion of survival in patients with metastatic castration-resistant prostate cancer but also engage a c

96 zole that was developed for the treatment of castration-resistant prostate cancer but was dropped in

97 ificant gains in the treatment of metastatic castration-resistant prostate cancer by radioligands tar

98 dex, clinicians and patients with metastatic castration-resistant prostate cancer can be reassured th

99 is study, we generated two anti-androgen and castration resistant prostate cancer cell models that do

100 lidated using a DNAJA1 inhibitor (116-9e) in castration-resistant prostate cancer cell (CRPC) and sph

101 xpression of miR-1205 were increased in both castration-resistant prostate cancer cell lines and in p

102 ive and an androgen-independent mechanism in castration-resistant prostate cancer cells.

103 occur early are an unmet need in metastatic castration-resistant prostate cancer clinical research a

104 sponse end points for early-phase metastatic castration-resistant prostate cancer clinical trials.

105 antiandrogen enzalutamide (Enz) extends the castration resistant prostate cancer (CRPC) patients' su

106 enzalutamide (Enz) has improved survival in castration resistant prostate cancer (CRPC) patients.

107 5alpha-dihydrotestosterone, respectively, in castration resistant prostate cancer (CRPC).

108 axis regulates multiple oncogenic drivers of castration resistant prostate cancer (CRPC).

109 er almost always recurs as a more aggressive castration resistant prostate cancer (CRPC).

110 oncogenic MUC1-C protein is overexpressed in castration-resistant prostate cancer (CRPC) and NEPC, bu

111 The precise molecular alterations driving castration-resistant prostate cancer (CRPC) are not clea

112 ent castration-sensitive phenotype to lethal castration-resistant prostate cancer (CRPC) are poorly u

113 inistered intravenously for the treatment of castration-resistant prostate cancer (CRPC) as the oral

114 or, improves survival in men with metastatic castration-resistant prostate cancer (CRPC) before and a

115 ndrogen-dependent prostate cancer (ADPC) and castration-resistant prostate cancer (CRPC) cell lines,

116 rapies have significantly improved survival, castration-resistant prostate cancer (CRPC) cells are ev

117 Finally, androgen-independent AR activity in castration-resistant prostate cancer (CRPC) cells is dri

118 environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical tri

119 d PET is potentially useful for screening of castration-resistant prostate cancer (CRPC) clinical tri

120 Castration-resistant prostate cancer (CRPC) continues to

121 Patients with metastatic castration-resistant prostate cancer (CRPC) frequently d

122 evels of BMI1 and that BMI1 was increased in castration-resistant prostate cancer (CRPC) from both hu

123 The view of castration-resistant prostate cancer (CRPC) has changed

124 tor antagonist approved for the treatment of castration-resistant prostate cancer (CRPC) in chemother

125 Finally, ZBTB7A suppressed the growth of castration-resistant prostate cancer (CRPC) in vitro and

126 The development of castration-resistant prostate cancer (CRPC) is associate

127 Castration-resistant prostate cancer (CRPC) is character

128 Castration-resistant prostate cancer (CRPC) is defined b

129 The lethal phenotype of castration-resistant prostate cancer (CRPC) is generally

130 Castration-resistant prostate cancer (CRPC) is the letha

131 Metastatic castration-resistant prostate cancer (CRPC) is the prima

132 Trials in castration-resistant prostate cancer (CRPC) need new cli

133 nce of prostate cancer either in the form of castration-resistant prostate cancer (CRPC) or transdiff

134 used clinical tissue from lethal metastatic castration-resistant prostate cancer (CRPC) patients obt

135 tably progress on AR-targeted therapies to a castration-resistant prostate cancer (CRPC) phenotype th

136 of AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) progression.

137 Castration-resistant prostate cancer (CRPC) remains a ma

138 en deprivation therapy (ADT) induces nMET in castration-resistant prostate cancer (CRPC) specimens.

139 s reactivated, signaling onset of the lethal castration-resistant prostate cancer (CRPC) stage.

140 ntinues to have a critical role in promoting castration-resistant prostate cancer (CRPC) survival and

141 Castration-resistant prostate cancer (CRPC) that has dev

142 the progression of prostate cancer (PCa) and castration-resistant prostate cancer (CRPC) through upre

143 rk [ACRIN] 6687) to a multicenter metastatic castration-resistant prostate cancer (CRPC) tissue bioma

144 benign prostate tissues, and even more so in castration-resistant prostate cancer (CRPC) tumors.

145 ough initially effective, leads to incurable castration-resistant prostate cancer (CRPC) via compensa

146 circulating tumor cells (CTCs) from men with castration-resistant prostate cancer (CRPC) was associat

147 ity due to prostate cancer happen because of castration-resistant prostate cancer (CRPC) which invari

148 3 ((223)Ra) can prolong survival in men with castration-resistant prostate cancer (CRPC) who have sym

149 onal therapy for chemotherapy-naive men with castration-resistant prostate cancer (CRPC) who range fr

150 Castration-resistant prostate cancer (CRPC) with neuroen

151 s the first therapeutic approach in treating castration-resistant prostate cancer (CRPC), but tumours

152 efficacy and promotes progression to lethal castration-resistant prostate cancer (CRPC), even when p

153 new insights into the molecular landscape of castration-resistant prostate cancer (CRPC), identifying

154 (LBD) are associated with the development of castration-resistant prostate cancer (CRPC), including r

155 r (NEPC), an extremely aggressive variant of castration-resistant prostate cancer (CRPC), is increasi

156 sistance to androgen deprivation therapy, or castration-resistant prostate cancer (CRPC), is often ac

157 articularly virulent form of this disease is castration-resistant prostate cancer (CRPC), where patie

158 o remission, the disease often progresses to castration-resistant prostate cancer (CRPC), which is st

159 e variants (AR-Vs) drives the progression of castration-resistant prostate cancer (CRPC).

160 P/FKBP51/IKKalpha complex and progression of castration-resistant prostate cancer (CRPC).

161 inevitably relapses and progresses to lethal castration-resistant prostate cancer (CRPC).

162 biraterone and enzalutamide in patients with castration-resistant prostate cancer (CRPC).

163 approval of abiraterone for the treatment of castration-resistant prostate cancer (CRPC).

164 genic pathways that contribute to metastatic castration-resistant prostate cancer (CRPC).

165 s receiving ADT eventually develop incurable castration-resistant prostate cancer (CRPC).

166 cancer deaths due to disease progression to castration-resistant prostate cancer (CRPC).

167 rapy failure leads to terminal and incurable castration-resistant prostate cancer (CRPC).

168 and PPP3CC is formed during the emergence of castration-resistant prostate cancer (CRPC).

169 is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC).

170 t al. expose new possibilities for targeting castration-resistant prostate cancer (CRPC).

171 o detect metastatic hormone-naive (HNPC) and castration-resistant prostate cancer (CRPC).

172 evelopment of novel treatment strategies for castration-resistant prostate cancer (CRPC).

173 potential therapeutic target for metastatic castration-resistant prostate cancer (CRPC).

174 of the predominantly upregulated pathways in castration-resistant prostate cancer (CRPC).

175 receptor (AR) activity are major drivers of castration-resistant prostate cancer (CRPC).

176 patients will relapse and develop incurable castration-resistant prostate cancer (CRPC).

177 ion inevitably drives disease progression to castration-resistant prostate cancer (CRPC).

178 one of the principal treatments for men with castration-resistant prostate cancer (CRPC).

179 ecific antigen can hamper early diagnosis of castration-resistant prostate cancer (CRPC).

180 are effective initially for the treatment of castration-resistant prostate cancer (CRPC).

181 ; however, therapy failure results in lethal castration-resistant prostate cancer (CRPC).

182 dministration in 2012 to treat patients with castration-resistant prostate cancer (CRPC).

183 V7 plays an important role in progression of castration-resistant prostate cancer (CRPC).

184 prostate cancer patients eventually develop castration-resistant prostate cancer (CRPC).

185 overall survival from endocrine therapies in castration-resistant prostate cancer (CRPC).

186 BET bromodomain inhibition in AR-independent castration-resistant prostate cancers (CRPC), whose freq

187 lind, phase 3 trial, men with nonmetastatic, castration-resistant prostate cancer (defined on the bas

188 Proteomic analysis of castration-resistant prostate cancer demonstrated the en

189 y androgen biosynthetic enzyme implicated in castration-resistant prostate cancer development.

190 relates with prostate cancer progression and castration-resistant prostate cancer development.

191 report that approximately 20% of metastatic castration-resistant prostate cancers express neither AR

192 progressing on androgen-deprivation therapy (castration-resistant prostate cancer) has improved subst

193 rovements to prognostic models in metastatic castration-resistant prostate cancer have the potential

194 y-naive patients with progressive metastatic castration-resistant prostate cancer in a 1:1 ratio to r

195 ) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer in a phase II study

196 tion of genomic stratification of metastatic castration-resistant prostate cancer in clinical practic

197 have shown promising activity in metastatic castration-resistant prostate cancers in single-group cl

198 Metastatic castration-resistant prostate cancer is enriched in DNA

199 th metastatic breast and six with metastatic castration-resistant prostate cancer, isolated via CellS

200 docetaxel cycles in patients with metastatic castration resistant prostate cancer (mCPRC) has not bee

201 ogens is a standard treatment for metastatic castration resistant prostate cancer (mCRPC), but it ine

202 widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC).

203 I]) in patients who have advanced metastatic castration-resistant prostate cancer (mCRPC) and are rec

204 lterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may con

205 linical data indicate activity in metastatic castration-resistant prostate cancer (mCRPC) and synergi

206 established prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) and the ass

207 o androgen receptor inhibition in metastatic castration-resistant prostate cancer (mCRPC) and whether

208 clear medicine is theranostics of metastatic castration-resistant prostate cancer (mCRPC) based on mo

209 ults in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC) but still e

210 sma DNA has been characterized in metastatic castration-resistant prostate cancer (mCRPC) but the pla

211 Metastatic castration-resistant prostate cancer (mCRPC) develops re

212 Metastatic castration-resistant prostate cancer (mCRPC) has a highl

213 Metastatic castration-resistant prostate cancer (mCRPC) is a hetero

214 Metastatic castration-resistant prostate cancer (mCRPC) is immunolo

215 ist enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) is undefine

216 cal decision in the management of metastatic castration-resistant prostate cancer (mCRPC) is when to

217 mic analysis of 429 patients with metastatic castration-resistant prostate cancer (mCRPC) linked with

218 tumor cells (CTC) from 179 unique metastatic castration-resistant prostate cancer (mCRPC) patients to

219 Whole-exome sequencing of metastatic castration-resistant prostate cancer (mCRPC) reveals tha

220 rogression-free survival (PFS) in metastatic castration-resistant prostate cancer (mCRPC) trials has

221 he OS in black and white men with metastatic castration-resistant prostate cancer (mCRPC) who were tr

222 d Methods Fifty-six patients with metastatic castration-resistant prostate cancer (mCRPC) with osseou

223 Purpose In patients with metastatic castration-resistant prostate cancer (mCRPC), overall su

224 precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we establi

225 -mesenchymal transition (EMT) and metastatic castration-resistant prostate cancer (mCRPC), which is c

226 eptor expression in patients with metastatic castration-resistant prostate cancer (mCRPC).

227 o detect lesions in patients with metastatic castration-resistant prostate cancer (mCRPC).

228 state cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC).

229 ses to treatment in patients with metastatic castration-resistant prostate cancer (mCRPC).

230 there are no curative options for metastatic castration-resistant prostate cancer (mCRPC).

231 g resistance mechanism to anti-AR therapy in castration-resistant prostate cancer (mCRPC).

232 lly significant co-occurrences in metastatic castration-resistant prostate cancer (mCRPC).

233 relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC).

234 nd therapy (RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC).

235 s), and subsequent progression to metastatic castration-resistant prostate cancer (mCRPC).

236 get for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC).

237 ty in men with previously treated metastatic castration-resistant prostate cancer (mCRPC).

238 rolled phase II trial in men with metastatic castration-resistant prostate cancer (mCRPC).

239 n a large cohort of patients with metastatic castration-resistant prostate cancer (mCRPC).

240 ) ((177)Lu-PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC).

241 graphic response in patients with metastatic castration-resistant prostate cancer (mCRPC).

242 ptake in skeletal metastases from metastatic castration-resistant prostate cancer (mCRPC).

243 PRLT) is an emerging treatment in metastatic castration-resistant prostate cancer (mCRPC).

244 Among men with nonmetastatic, castration-resistant prostate cancer, metastasis-free su

245 metastatic disease to management of men with castration-resistant prostate cancer metastatic to bone.

246 ion of patients for a specific treatment for castration-resistant prostate cancer or the best sequenc

247 d matched transcriptome data from metastatic castration resistant prostate cancer patients and redisc

248 PET/CT in the prediction of survival in both castration-resistant prostate cancer patients and hormon

249 e PET/CT as a diagnostic tool for monitoring castration-resistant prostate cancer patients treated wi

250 Thirty-five castration-resistant prostate cancer patients with multi

251 iation therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with prost

252 te cancer cell lines and cfDNA obtained from castration-resistant prostate cancer patients.

253 u-PSMA) radionuclide treatment in metastatic castration-resistant prostate cancer patients.

254 te cancer (NEPC), the most lethal subtype of castration-resistant prostate cancer (PCa), for which th

255 overall survival in patients with metastatic castration-resistant prostate cancer previously treated

256 or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated

257 8 years or older with progressing metastatic castration-resistant prostate cancer previously treated

258 tandard of care for patients with metastatic castration-resistant prostate cancer progressing after d

259 ing markers for AR/AR-variant expression and castration-resistant prostate cancer progression.

260 ults show nelfinavir and its analogs inhibit castration-resistant prostate cancer proliferation by bl

261 Patients with non-metastatic, castration-resistant prostate cancer receiving enzalutam

262 ate homologous recombination (HR) defects in castration-resistant prostate cancers, rendering these t

263 1GSC treatments in mouse xenograft models of castration-resistant prostate cancer resulted in signifi

264 e-capture RNA-seq dataset from 47 metastatic castration-resistant prostate cancer samples and ribodep

265 ndred consecutive patients with metastasized castration-resistant prostate cancer scheduled for PSMA

266 In castration-resistant prostate cancer specimens, the copy

267 rom 294 patients with progressing metastatic castration-resistant prostate cancer taken prior to star

268 with radiographically documented metastatic castration-resistant prostate cancer that had progressed

269 to evaluate BAT in patients with metastatic castration-resistant prostate cancer that progressed aft

270 amined orteronel in patients with metastatic castration-resistant prostate cancer that progressed aft

271 d characterization of circRNAs in metastatic castration-resistant prostate cancer, the major cause of

272 Among men with nonmetastatic, castration-resistant prostate cancer, the percentage of

273 nhibit proliferation and induce apoptosis of castration-resistant prostate cancer through inhibition

274 ses are highly expressed in human metastatic castration-resistant prostate cancer tissues.

275 t randomised clinical trials with metastatic castration-resistant prostate cancer to estimate the gro

276 gen and antiandrogen therapies in metastatic castration-resistant prostate cancer to maximise therape

277 ficantly longer for patients with metastatic castration-resistant prostate cancer treated with this c

278 EGFR associated with the LIFR and SUCLG2 in castration-resistant prostate cancer tumors.

279 iation dosimetry, 4 patients with metastatic castration-resistant prostate cancer underwent serially

280 e 3 clinical trials in first-line metastatic castration-resistant prostate cancer were obtained from

281 rmance status <=2) with confirmed metastatic castration-resistant prostate cancer were randomly assig

282 Data from 13 patients with metastatic castration-resistant prostate cancer were retrospectivel

283 USE M1-in which 266 patients with metastatic castration-resistant prostate cancer were treated with p

284 hesis and prolongs survival in patients with castration-resistant prostate cancer, which is otherwise

285 r enzalutamide), in patients with metastatic castration-resistant prostate cancer who had been previo

286 patients (mean age, 72.9 y) with metastatic castration-resistant prostate cancer who had been referr

287 RP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease pro

288 In men with metastatic castration-resistant prostate cancer who had disease pro

289 ds: Fifty patients with PSMA-avid metastatic castration-resistant prostate cancer who had progressed

290 ide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying

291 Among men with metastatic castration-resistant prostate cancer who had tumors with

292 r enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously

293 fit of treating STEAP1-expressing metastatic castration-resistant prostate cancer with an STEAP1-targ

294 b has antitumour activity against metastatic castration-resistant prostate cancer with DDR gene aberr

295 Furthermore, patients with castration-resistant prostate cancer with increased tumo

296 ve seen the start of treatment of metastatic castration-resistant prostate cancer with prostate-speci

297 d no survival benefit in men with metastatic castration-resistant prostate cancer with the addition o

298 rmed progressive bone-predominant metastatic castration-resistant prostate cancer with two or more sk

299 d and radiographically documented metastatic castration-resistant prostate cancer, with no more than

300 patients with chemotherapy-naive metastatic castration-resistant prostate cancer without visceral me